By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Antipsychotic > Aripiprazole

Aripiprazole

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|631 words

What is Aripiprazole?

Aripiprazole is an atypical antipsychotic medication used to treat various mental health conditions. It belongs to a class of drugs called second-generation or atypical antipsychotics, which work differently from older antipsychotic medications. Aripiprazole is primarily prescribed for schizophrenia, bipolar disorder, and as an add-on treatment for major depressive disorder.

Uses

Aripiprazole has several FDA-approved uses for treating mental health conditions:

  • Schizophrenia: Helps manage symptoms like hallucinations, delusions, and disorganized thinking in adults and adolescents aged 13 and older
  • Bipolar I disorder: Used for acute treatment of manic and mixed episodes, and for maintenance therapy to prevent mood episodes
  • Major depressive disorder: Prescribed as an adjunctive treatment alongside antidepressants when depression doesn’t respond adequately to antidepressant therapy alone
  • Irritability associated with autism: Approved for treating irritability in children and adolescents with autism spectrum disorder, ages 6-17
  • Tourette’s disorder: Used to help control motor and vocal tics in children and adolescents aged 6-18

How it works

Aripiprazole works as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, while acting as an antagonist at serotonin 5-HT2A receptors. This unique mechanism allows it to stabilize dopamine activity in the brain rather than simply blocking it, which may reduce the risk of certain side effects common with traditional antipsychotics. By modulating these neurotransmitter systems, aripiprazole helps restore the chemical balance that affects mood, thinking, and behavior.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and vomiting
  • Headache
  • Dizziness
  • Anxiety or restlessness
  • Insomnia or sleep disturbances
  • Constipation
  • Weight gain
  • Fatigue

Serious side effects to watch for:

  • Tardive dyskinesia (involuntary muscle movements)
  • Neuroleptic malignant syndrome (fever, muscle rigidity, altered mental status)
  • Severe allergic reactions
  • Suicidal thoughts or behaviors, especially in young adults
  • Significant changes in blood sugar or cholesterol levels

Warnings and precautions

  • Elderly patients with dementia: Increased risk of death when antipsychotics are used to treat dementia-related psychosis; aripiprazole is not approved for this use
  • Pregnancy: Should only be used during pregnancy if potential benefits justify risks to the fetus; may cause withdrawal symptoms in newborns
  • Suicidal ideation: Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, particularly during the first few months of treatment
  • Metabolic effects: Can cause weight gain and changes in blood sugar and cholesterol levels; regular monitoring is recommended
  • Movement disorders: Risk of tardive dyskinesia increases with longer treatment duration and higher doses

Interactions

  • CYP2D6 inhibitors (fluoxetine, paroxetine): Can increase aripiprazole levels, requiring dose reduction
  • CYP3A4 inducers (carbamazepine, rifampin): May decrease aripiprazole effectiveness by reducing blood levels
  • CYP3A4 inhibitors (ketoconazole, clarithromycin): Can increase aripiprazole concentrations and side effects
  • Central nervous system depressants (alcohol, benzodiazepines): May enhance sedative effects and impair coordination
  • Antihypertensive medications: Aripiprazole may enhance blood pressure-lowering effects
  • Levodopa and dopamine agonists: Aripiprazole may reduce their effectiveness due to dopamine receptor antagonism
  • St. John’s Wort: May decrease aripiprazole levels by inducing liver enzymes
  • Quinidine: Strong CYP2D6 inhibitor that can significantly increase aripiprazole levels

Check interactions with the GMJ Interaction Checker

Dosage

Aripiprazole dosing varies significantly based on the condition being treated and individual patient factors. For schizophrenia, the typical adult starting dose is 10-15 mg once daily, with a usual maintenance range of 10-30 mg daily. For bipolar disorder, doses typically range from 15-30 mg daily. When used as adjunctive therapy for depression, lower doses of 2-15 mg daily are common. The medication is usually taken once daily and can be taken with or without food. Dosage adjustments may be necessary based on individual response, side effects, and drug interactions. A healthcare provider should always determine the appropriate dose and monitor treatment response.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Aripiprazole." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/aripiprazole/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Magnesium’s hidden role in insulin signalling: why the mineral matters for glucose control

Magnesium acts as a critical molecular switch in insulin signalling. New analysis…

Why the same bread raises blood sugar differently in different people

Researchers at the Weizmann Institute found that identical carbohydrate meals produce glucose…

Vitamin D dose response is not linear: Why shelf-picked supplements may not work as expected

Vitamin D supplements do not work the same way for everyone. Research…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Chlorpromazine

By
Prof. Giorgi Pkhakadze
02/06/2026

Ziprasidone

By
Prof. Giorgi Pkhakadze
02/06/2026

Quetiapine

By
Prof. Giorgi Pkhakadze
02/06/2026

Haloperidol

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up